SCHEMBL29173533

SCHEMBL29173533

COC(=O)c1nc(-c2cncc3c2ncn3C)c(SC)nc1Nc1ccc(N2CCOCC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.38
▸ PKMYT1 Q99640 3/20 0.38
▸ ALK Q9UM73 2/20 0.37
▸ INSR P06213 1/20 0.37
▸ EML4 Q9HC35 1/20 0.36
▸ CDK2 P24941 3/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ NTRK1 P04629 2/20 0.36
▸ YES1 P07947 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ CCNA2 P20248 2/20 0.36
▸ CDK4 P11802 2/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HIPK1 Q86Z02 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ AURKA O14965 1/20 0.36
▸ CCND3 P30281 1/20 0.36
▸ CDK6 Q00534 1/20 0.36
▸ CCNA1 P78396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24944736 0.92 EML4 (0.45) BTKPKMYT1ALKEML4CDK2
SCHEMBL30205584 0.92 EML4 (0.45) BTKPKMYT1ALKEML4CDK2
SCHEMBL30206147 0.90 PKMYT1 (0.41) BTKPKMYT1ALKINSRCDK2
SCHEMBL29173512 0.89 PKMYT1 (0.40) PKMYT1ALKINSREML4CDK2
SCHEMBL30206202 0.89 PKMYT1 (0.40) PKMYT1ALKINSREML4CDK2
SCHEMBL30206153 0.88 PKMYT1 (0.38) PKMYT1ALKINSREML4CDK2
SCHEMBL30206250 0.88 CDK2 (0.40) PKMYT1ALKINSREML4CDK2
SCHEMBL29173439 0.88 PKMYT1 (0.38) PKMYT1ALKINSREML4CDK2
SCHEMBL29173475 0.88 CDK2 (0.40) PKMYT1ALKINSREML4CDK2
SCHEMBL29173457 0.87 CDK2 (0.39) PKMYT1ALKINSREML4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 BTK 2111/4885PKMYT1 587/4885ALK 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback